Table 2 Postoperative RT III clinical trials
From: Progress of preoperative and postoperative radiotherapy in gastric cancer
Study/institute | n | D2 | RT | pN+ | III-IV | DFS/RFS | OS | Remarks |
|---|---|---|---|---|---|---|---|---|
2001 INT0116 USA [3] | 556 | 10% | 2D | 85% | NR | 3-year 48% vs. 31% (p < 0.001) | 3-year 50% vs. 41% (p = 0.005) |  |
2012 INT0116 [23] | Â | Â | Â | Â | Â | 10-year similar | 10-year similar | D1 and D2 benefit |
2012 ARTIST South Korea [24] | 458 | 100% | 2D or 3D | 86% | 41% | 3-year 78% vs. 74% (p = 0.0862) | NR | N+DFS benefit |
2015 ARTIST Final report [25] |  |  |  |  |  | 5-year 74% vs. 68% (p = 0.092) | 5-year 75% vs. 73% (p = 0.527) | N+ and GC DFS benefit |
2012 NCC South Korea [26] | 90 | 100% | 2D or 3D | 98% | 100% | 5-year 65% vs. 55% (p > 0.05) | 5-year 65% vs. 55% (p > 0.05) | LRRFS and III stage DFS benefit |
2012 IMRT China [27] | 351 | 100% | NR | 86% | 71% | 5-year 45% vs. 36% (p = 0.029) | 5-year 48% vs. 42% (p = 0.122) |  |